Zayda Piedra, PhD

Chimeric antigen receptor (CAR)-T cell therapy is an approach that uses T cells (a type of immune cell) to fight cancer. In this therapy, T cells are modified to express a receptor that helps them recognize and eventually destroy specific cancer cells. Highly controlled cell culture environments allow the expansion, activation, and differentiation of T cells with the right therapeutic profile. Thus, to obtain consistent quality and performance, bioprocessing reagents with defined formulations and animal-free ingredients are critical during T cell manufacture. Dr. Zayda Piedra, PhD discusses a much-desired workflow solution BioLegend is developing for CAR-T cell therapy to support the progression of research into clinical applications.

 

What you will learn:

• CAR-T cell therapy workflow components, from research to treatment.
• Current challenges in the cell therapy industry and what can we do better.
• BioLegend emerging solutions for T cell therapy - closing the gaps, one at the time.
• Importance of bioprocessing reagents manufactured with consistent, high-quality well-defined components.